| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255887P | 2015-11-16 | 2015-11-16 | |
| PCT/US2016/062052WO2017087395A1 (en) | 2015-11-16 | 2016-11-15 | Materials and methods for treatment of titin-based myopathies and other titinopaties |
| Publication Number | Publication Date |
|---|---|
| SG11201804166YAtrue SG11201804166YA (en) | 2018-06-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804166YASG11201804166YA (en) | 2015-11-16 | 2016-11-15 | Materials and methods for treatment of titin-based myopathies and other titinopaties |
| Country | Link |
|---|---|
| US (2) | US11617783B2 (en) |
| EP (1) | EP3377042A4 (en) |
| JP (3) | JP7418957B2 (en) |
| KR (1) | KR20180081600A (en) |
| CN (1) | CN108463211B (en) |
| AU (1) | AU2016358172B2 (en) |
| BR (1) | BR112018009954A2 (en) |
| CA (1) | CA3005633C (en) |
| CO (1) | CO2018006133A2 (en) |
| EA (1) | EA201891192A1 (en) |
| HK (1) | HK1257955A1 (en) |
| IL (1) | IL259441B2 (en) |
| MX (1) | MX2018006116A (en) |
| NZ (2) | NZ782095A (en) |
| SG (1) | SG11201804166YA (en) |
| WO (1) | WO2017087395A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (en) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND PROCEDURES FOR PREDICTING REPAIR RESULTS IN GENE ENGINEERING |
| MY209273A (en) | 2018-01-31 | 2025-06-30 | Res Inst Nationwide Childrens Hospital | Gene therapy for limb-girdle muscular dystrophy type 2c |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| CA3105216A1 (en)* | 2018-06-29 | 2020-01-02 | Research Institute At Nationwide Children's Hospital | Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020229340A1 (en) | 2019-02-26 | 2021-09-16 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy |
| WO2020191246A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US12258573B2 (en) | 2019-08-21 | 2025-03-25 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy |
| WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
| AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| US12171813B2 (en) | 2021-02-05 | 2024-12-24 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| CN113512536A (en)* | 2021-05-07 | 2021-10-19 | 山东大学深圳研究院 | A kit for preparing human dopamine neurons and its application |
| EP4219726A1 (en) | 2021-10-15 | 2023-08-02 | Research Institute at Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| WO2023190935A1 (en)* | 2022-03-31 | 2023-10-05 | Modalis Therapeutics Corporation | Method for treating myopathies by targeting titin gene |
| US20250268992A1 (en)* | 2022-04-25 | 2025-08-28 | The Jackson Laboratory | Methods for treating dilated cardiomyopathy and pharmaceutical compositions therefor |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1995013392A1 (en) | 1993-11-09 | 1995-05-18 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
| PT733103E (en) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | CREATION OF HIGH RECOMBINANT AAV VECTOR TITLES |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| JPH10511264A (en) | 1994-12-06 | 1998-11-04 | ターゲティッド ジェネティックス コーポレイション | Packaging cell lines for the production of high titer recombinant AAV vectors |
| FR2737730B1 (en) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY |
| CA2230655C (en) | 1995-08-30 | 2008-06-17 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| JPH11514853A (en) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | Improved AAV vector for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP1009808B1 (en) | 1997-09-05 | 2012-12-05 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| WO2007049095A1 (en)* | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
| KR101240487B1 (en)* | 2006-11-09 | 2013-03-08 | 더 존스 홉킨스 유니버시티 | Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells |
| US20110023139A1 (en)* | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of genes involved in cardiovascular disease |
| FR2962041B1 (en) | 2010-07-01 | 2012-07-27 | Genethon | INHIBITORS OF CALPAIN 3 FOR THE TREATMENT OF MUSCULAR DYSTROPHIES AND CARDIOMYOPATHIES |
| FI3597749T3 (en) | 2012-05-25 | 2023-10-09 | Univ California | METHODS AND COMPOSITIONS FOR RNA-DIRECTED MODIFICATION OF TARGET DNA AND RNA-DIRECTED MODULATION OF TRANSCRIPTION |
| EP2900821B1 (en)* | 2012-09-25 | 2020-04-01 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| IL293526A (en) | 2012-12-12 | 2022-08-01 | Harvard College | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| EP4279588A3 (en)* | 2012-12-12 | 2024-01-17 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| JP2016505256A (en) | 2012-12-12 | 2016-02-25 | ザ・ブロード・インスティテュート・インコーポレイテッ | CRISPR-Cas component system, method and composition for sequence manipulation |
| EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| TW201536329A (en) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | Compound and method for regulating the manifestation of dystrophic myotonic protein kinase (DMPK) |
| US9850497B2 (en)* | 2013-11-04 | 2017-12-26 | Regents Of The University Of Minnesota | Gene targeting methods and tools |
| KR20160089526A (en)* | 2013-12-12 | 2016-07-27 | 더 브로드 인스티튜트, 인코퍼레이티드 | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| Publication number | Publication date |
|---|---|
| US20230233651A1 (en) | 2023-07-27 |
| EP3377042A1 (en) | 2018-09-26 |
| CA3005633A1 (en) | 2017-05-26 |
| JP2023184679A (en) | 2023-12-28 |
| NZ782095A (en) | 2025-06-27 |
| JP2018533959A (en) | 2018-11-22 |
| KR20180081600A (en) | 2018-07-16 |
| IL259441B1 (en) | 2023-09-01 |
| US11617783B2 (en) | 2023-04-04 |
| JP2022009734A (en) | 2022-01-14 |
| US20180360921A1 (en) | 2018-12-20 |
| EP3377042A4 (en) | 2019-05-29 |
| CO2018006133A2 (en) | 2018-08-31 |
| CA3005633C (en) | 2023-11-21 |
| JP7418957B2 (en) | 2024-01-22 |
| BR112018009954A2 (en) | 2018-11-13 |
| NZ742751A (en) | 2025-06-27 |
| IL259441B2 (en) | 2024-01-01 |
| HK1257955A1 (en) | 2019-11-01 |
| EA201891192A1 (en) | 2019-01-31 |
| AU2016358172A1 (en) | 2018-06-07 |
| AU2016358172B2 (en) | 2023-06-22 |
| MX2018006116A (en) | 2019-04-04 |
| IL259441A (en) | 2018-07-31 |
| CN108463211B (en) | 2022-09-27 |
| CN108463211A (en) | 2018-08-28 |
| WO2017087395A1 (en) | 2017-05-26 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804166YA (en) | Materials and methods for treatment of titin-based myopathies and other titinopaties | |
| SG11201808812RA (en) | Novel aav8 mutant capsids and compositions containing same | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
| SG11201809144XA (en) | Materials and methods for treatment of hemoglobinopathies | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201907474UA (en) | Compositions useful in treatment of spinal muscular atrophy | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201804856VA (en) | C-terminal lysine conjugated immunoglobulins | |
| SG11201810010PA (en) | Methods and compositions for treatment of concrete wash water | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors |